United Therapeutics (NASDAQ:UTHR) has filed litigation in a Delaware court against Liquidia Technologies (NASDAQ:LQDA) in response to the latter's U.S. marketing application seeking approval of LIQ861, a dry powder inhalation formulation of treprostinil.
The lawsuit claims LIQ861 infringes on U.S. Patent No. 10,716,793 related to Tyvaso (treprostinil) Inhalation Solution.
The action triggers an automatic 30-month stay on FDA approval of LIQ861 to allow time for the matter to be adjudicated.
David S. Brown Enterprises has bolstered its Retail Leasing team with the recent hiring of Michael Gosnell
Kennedy Krieger Institute has announced the appointment of Dr. John Campo as Vice President of Psychiatric Services
Pessin Katz Law is pleased to announce that Attorney Adam E. Konstas has been elected to Member
Knollwood, the premier life plan community of choice for those 62 and better in NW Washington, D.C., known for
Editor in Chief, Warfield Digital
Connect
Independent Consultant
Connect
President of Lawrence Howard & Associates
Connect
Partner at Womble Carlyle, LLP
Connect
Owner at Develop DC
Connect
Stinson Marketing Group
Connect
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2026 citybuzz
